Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a …
J Kovalchin, J Krieger, M Genova, K Collins… - Journal of …, 2010 - Elsevier
PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-
controlled, multiple-ascending dose, double-blind study was performed in patients with
secondary-progressive MS. Treatment was given subcutaneously once weekly for 8weeks,
followed by a 4-week open-label treatment period with active drug. The most common
adverse event was transient injection site reactions. Non-significant trend for increases in
serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial TH2 …
controlled, multiple-ascending dose, double-blind study was performed in patients with
secondary-progressive MS. Treatment was given subcutaneously once weekly for 8weeks,
followed by a 4-week open-label treatment period with active drug. The most common
adverse event was transient injection site reactions. Non-significant trend for increases in
serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial TH2 …